News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
Steve Powell has been appointed CEO of SynteractHCR Holdings Corporation, succeeding Wendel Barr who has left the company after six years as CEO.
“My goal is to ensure continued innovation to address customer needs, regardless of the direction they take, and to enable breakthroughs in both operations and technology, as well as expert services, to bring drugs to market faster, more cost effectively and safely,” Powell told Outsourcing-Pharma.com.